Literature DB >> 15661507

Physical solid-state properties and dissolution of sustained-release matrices of polyvinylacetate.

Gelsys Ananay Gonzalez Novoa1, Jyrki Heinämäki, Sabir Mirza, Osmo Antikainen, Antonio Iraizoz Colarte, Alberto Suzarte Paz, Jouko Yliruusi.   

Abstract

Solid-state compatibility and in vitro dissolution of direct-compressed sustained-release matrices of polyvinylacetate (PVAc) and polyvinylpyrrolidone (PVP) containing ibuprofen as a model drug were studied. Polyvinylalcohol (PVA) was used as an alternative water-soluble polymer to PVP. Differential scanning calorimetry (DSC) and powder X-ray diffractometry (PXRD) were used for characterizing solid-state polymer-polymer and drug-polymer interactions. The mechanical treatment for preparing physical mixtures of polyvinyl polymers and the drug (i.e. simple blending or stressed cogrinding) was shown not to affect the physical state of the drug and the polymers. With the drug-polymer mixtures the endothermic effect due to drug melting was always evident, but a considerable modification of the melting point of the drug in physical binary mixtures (drug:PVP) was observed, suggesting some interaction between the two. On the other hand, the lack of a significant shift of the melting endothermic peak of the drug in physical tertiary drug-polymer mixtures revealed no evidence of solid-state interaction between the drug and the present polymers. Sustained-release dissolution profiles were achieved from the direct-compressed matrices made from powder mixtures of the drug and PVAc combined with PVP, and the proportion of PVAc in the mixture clearly altered the drug release profiles in vitro. The drug release from the present matrix systems is controlled by both diffusion of the drug through the hydrate matrix and the erosion of the matrix itself.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15661507     DOI: 10.1016/j.ejpb.2004.07.012

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  7 in total

1.  Once daily, high-dose mesalazine controlled-release tablet for colonic delivery: optimization of formulation variables using Box-Behnken design.

Authors:  Ahmed Abd Elbary; Ahmed A Aboelwafa; Ibrahim M Al Sharabi
Journal:  AAPS PharmSciTech       Date:  2011-10-29       Impact factor: 3.246

2.  Effects of thermal curing conditions on drug release from polyvinyl acetate-polyvinyl pyrrolidone matrices.

Authors:  Hatim S Alkhatib; Saja Hamed; Mohammad K Mohammad; Yasser Bustanji; Bashar Alkhalidi; Khaled M Aiedeh; Samer Najjar
Journal:  AAPS PharmSciTech       Date:  2010-02-20       Impact factor: 3.246

3.  In vitro release kinetics and physical, chemical and mechanical characterization of a POVIAC®/CaCO3/HAP-200 composite.

Authors:  Javier Aragón; Ramón González; Gastón Fuentes; Luca Palin; Gianluca Croce; Davide Viterbo
Journal:  J Mater Sci Mater Med       Date:  2011-12-27       Impact factor: 3.896

4.  Screening of lipid carriers and characterization of drug-polymer-lipid interactions for the rational design of polymer-lipid hybrid nanoparticles (PLN).

Authors:  Yongqiang Li; Nicolas Taulier; Andrew M Rauth; Xiao Yu Wu
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

5.  Polymer coating of paramagnetic particulates for in vivo oxygen-sensing applications.

Authors:  Edward Eteshola; Ramasamy P Pandian; Stephen C Lee; Periannan Kuppusamy
Journal:  Biomed Microdevices       Date:  2009-04       Impact factor: 2.838

6.  Composite poly(vinyl alcohol)/poly(vinyl acetate) electrospun nanofibrous mats as a novel wound dressing matrix for controlled release of drugs.

Authors:  Marziyeh Jannesari; Jaleh Varshosaz; Mohammad Morshed; Maedeh Zamani
Journal:  Int J Nanomedicine       Date:  2011-05-19

7.  Risk assessment and experimental design in the development of a prolonged release drug delivery system with paliperidone.

Authors:  Sonia Iurian; Luana Turdean; Ioan Tomuta
Journal:  Drug Des Devel Ther       Date:  2017-03-13       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.